Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg,...
-
Upload
caroline-holmes -
Category
Documents
-
view
219 -
download
4
Transcript of Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg,...
![Page 1: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/1.jpg)
Operational Analysis
National Gene Vector Biorepository
Aaron Boeke, Kevin Largent, Kyle McClurg, Sean SeacatNot present: Patrick Doumas and Peter Tichenor
Faculty Advisor: Prof. Mohan V. Tatikonda ([email protected])
February 22, 2012
![Page 2: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/2.jpg)
Agenda
• Background• Investigation• Problem Definition• Project Overview • Questions
![Page 3: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/3.jpg)
Background• Mission of the National Gene Vector
Biorepository (NGVB) is to provide gene therapy investigators with a variety of services that can enhance their research.o Archiving Serviceso Insertion Site Analysiso Pharmacology and Toxicology Resourceso Reagent Repository
• Housed within the Department of Medical and Molecular Genetics in the IUSM.o Made possible by a grant from the National
Center for Research Resources (NCRR)
![Page 4: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/4.jpg)
Objective
• NGVB requested assistance from a Kelley MBA team to:o (1) analyze workflow; o (2) make suggestions for improved internal
and external communications; and o (3) develop a system to manage inputs and
outputs.
![Page 5: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/5.jpg)
Defining the Problem• Discussed concerns with NGVB manager
o Weekly meetings• Toured the NGVB Facilities
o Certification Labo Freezer and Deep-Freeze Storage Sites
• Met with staff to better understand gene therapy research environmento Troy Hawkins - Molecular Diagnostics
Supervisoro Lisa Duffy - Certification Lab Supervisor
![Page 6: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/6.jpg)
Defining the Problem We also reviewed:
o Standard operating procedureso Initial customer informationo Product/service catalogo Stepped through the customer’s order entry
process using the NGVB websiteo Worked to understand each step an order
goes through in the process
![Page 7: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/7.jpg)
Initial Findings• Current process documentation can be enhanced
o General o Customer problems
• Lack of standardizationo Labeling and storage of productso Use of electronic database across product
lines• Uncertainty regarding the quality of the
customer's experience• Uncertainty of demand across product lines
o Difficulty in determining batch sizes, stock levels, and reorder points
![Page 8: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/8.jpg)
Process Analysis• Process Flow Diagrams
o Current state mapped to gain primary understanding of the NGVB processes Observe processes to understand the
physical flow of materials, people, and information
Determine constraints and sources of variation
• Increase Service Level to the Customero Decreased turn-around time
![Page 9: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/9.jpg)
![Page 10: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/10.jpg)
Customer Analysis
• Database analysiso Variety, volume, and frequency of orders
• Qualitative interviews with local customerso Analyze experiences of customers from a
variety of perspectives new vs. repeat customers local vs. international frequent vs. infrequent
![Page 11: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/11.jpg)
Intended Deliverables • Detailed process characterization and capacity
analysis o Bottleneck identificationo Flow time analysis
• Analysis of current customer set and historical order patternso Demand forecastingo Production schedulingo Improved customer order fulfillment time
• Optimization of storage capacity
![Page 12: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/12.jpg)
IU Vector Production Facility
• Background
o Provides gene therapy production and testing services with a focus on lentiviral gene transfer
• Project- In Project Scope Phaseo Provide detailed understanding of overhead
cost in order to appropriately price serviceso Working in compliance with FDA and
NIH regulations and guidelines
![Page 13: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.](https://reader035.fdocuments.us/reader035/viewer/2022071716/56649eca5503460f94bd8f76/html5/thumbnails/13.jpg)
Questions?
Thank you